Atg16L2 Activators

Atg16L2 Activators are a class of chemical compounds that provoke an indirect increase in the functional activity of Atg16L2, a protein that plays a critical role in autophagosome formation. These activators span a range of diverse chemical structures and mechanisms of action, unified by their common endpoint of enhancing Atg16L2 function via autophagy modulation. An important group within this class includes mTOR inhibitors such as Rapamycin and Torin 1, which induce autophagy by inhibiting the mTOR pathway, a central regulator of cellular growth and an inhibitor of autophagy. The induction of autophagy by these compounds thereby leads to a rise in Atg16L2 activation due to the protein's pivotal role in autophagosome formation. Furthermore, Epoxomicin, a potent proteasome inhibitor, also falls within this class. By inhibiting proteasome function, it induces autophagy as a compensatory mechanism for intracellular protein degradation, leading to enhanced Atg16L2 activity.

Another group within the Atg16L2 Activators class includes compounds that alter lysosome function, which indirectly influences Atg16L2 function. For instance, Chloroquine and Hydroxychloroquine block autophagy by inhibiting lysosomes, leading to an upsurge in autophagosome formation and, consequently, Atg16L2 activation. Bafilomycin A1, another member of this group, inhibits vacuolar H+ ATPase, disrupting the acidification of intracellular compartments and increasing autophagy activity. This class also includes PI3K inhibitors, such as Wortmannin and LY294002. While these compounds typically block autophagy, they can lead to compensatory autophagy mechanisms that enhance Atg16L2 function. Lastly, autophagy inducers like Tamoxifen, Verapamil, and Trehalose, by inducing autophagy, inherently enhance Atg16L2 function, affirming their place in the Atg16L2 Activators class.